|
1
|
Jurczak W, Shah NN, Lamanna N, Eyre TA, Woyach J, Lech‐Maranda E, Wierda WG, Lewis D, Thompson MC, Wang D, Yin M, Balbas M, Nair BC, Zhu EY, Tsai DE, Ku NC, Coombs CC, Mato AR. PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.41_2880] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- W. Jurczak
- Maria Sklodowska‐Curie National Research Institute of Oncology Clinical Oncology Krakow Poland
| | - N. N. Shah
- Medical College of Wisconsin Hematology and Oncology Brookfield USA
| | - N. Lamanna
- Herbert Irving Comprehensive Cancer Center Columbia University, Medicine New York USA
| | - T. A. Eyre
- Oxford University Hospitals NHS Foundation Trust Churchill Cancer Center Haematology Oxford UK
| | - J. Woyach
- The Ohio State University Comprehensive Cancer Center Internal Medicine Columbus USA
| | - E. Lech‐Maranda
- Institute of Hematology and Transfusion Medicine Hematology Warsaw Poland
| | | | - D. Lewis
- Plymouth Hospitals NHS Trust ‐ Derriford Hospital Haematology Plymouth UK
| | - M. C. Thompson
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - D. Wang
- Loxo Oncology at Lilly Statistics Stamford USA
| | - M. Yin
- Loxo Oncology at Lilly Statistics Stamford USA
| | - M. Balbas
- Loxo Oncology at Lilly, Clinical Stamford CT USA
| | - B. C. Nair
- Loxo Oncology at Lilly, Clinical Stamford CT USA
| | - E. Y. Zhu
- Loxo Oncology at Lilly, Clinical Stamford CT USA
| | - D. E. Tsai
- Loxo Oncology at Lilly, Medical Stamford CT USA
| | - N. C. Ku
- Loxo Oncology at Lilly, Medical Stamford CT USA
| | - C. C. Coombs
- University of North Carolina at Chapel Hill Medicine Chapel Hill USA
| | - A. R. Mato
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| |
Collapse
|
|
2
|
Ghia P, Flinn I, Lamanna N, Montillo M, Illés Á, Etienne G, Delgado J, Kuss B, Tam C, Offner F, Bosch F, Davids M, Jäger U, Cymbalista F, Weaver D, Lustgarten S, Youssoufian H, Stilgenbauer S. EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.30_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Ghia
- Division of Experimental Oncology; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele; Milan Italy
| | - I.W. Flinn
- Lymphoma Research; Sarah Cannon Research Institute; Nashville TN United States
| | - N. Lamanna
- Department of Medicine Division of Hematology/Oncology; New York Presbyterian, Columbia University Medical Center; New York NY United States
| | - M. Montillo
- Department of Haematology and Oncology; Niguarda Cancer Center, Niguarda Hospital; Milan Italy
| | - Á. Illés
- Department of Hematology; Faculty of Medicine, University of Debrecen; Debrecen Hungary
| | - G. Etienne
- Hematology Department; Institut Bergonie; Bordeaux France
| | - J. Delgado
- Department of Hematology; Hospital Clinic; Barcelona Spain
| | - B.J. Kuss
- Molecular Medicine and Pathology; Flinders Medical Centre-Flinders University; Bedford Park Australia
| | - C.S. Tam
- Division of Hematology and Oncology; Peter MacCallum Cancer Centre, St Vincent's Hospital and University of Melbourne; Melbourne Australia
| | - F. Offner
- Hematology; University Hospital Ghent; Gent Belgium
| | - F. Bosch
- Department of Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | - M.S. Davids
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - U. Jäger
- Division of Hematology and Hemostaseology; Department of Medicine I, Medical University of Vienna; Wien Austria
| | - F. Cymbalista
- Laboratoire d'hématologie; Hôpital Avicenne; Paris France
| | - D.T. Weaver
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - S. Lustgarten
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - H. Youssoufian
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - S. Stilgenbauer
- Department III of Internal Medicine; University Hospital Ulm; Ulm Germany
| |
Collapse
|
|
3
|
Mato A, Schuster S, Lamanna N, Pagel J, Flinn I, Barrientos J, Reeves J, Cheson B, Barr P, Kambhampati S, Lansigan F, Pu J, Skarbnik A, Fonseca G, Dorsey C, LaRatta N, Weissbrot H, Svoboda J, Luning Prak E, Tsao P, Sitlinger A, Paskalis D, Sportelli P, Miskin H, Weiss M, Brander D. A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.56_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A.R. Mato
- CLL Program; Leukemia Service, Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - S.J. Schuster
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - N. Lamanna
- Columbia University Medical Center; New York-Presbyterian; New York United States
| | - J.M. Pagel
- Department of Hematology; Swedish Cancer Institute; Seattle WA United States
| | - I.W. Flinn
- TN Oncology; Sarah Cannon Research Institute; Nashville TN United States
| | - J. Barrientos
- CLL Research and Treatment Program; Northwell Health; New Hyde Park NY United States
| | - J.A. Reeves
- Florida Cancer Specialists; Sarah Cannon Research Institute; Fort Myers FL United States
| | - B.D. Cheson
- Lombardi Comprehensive Cancer Center; Georgetown University Hospital; Washington DC United States
| | - P.M. Barr
- Wilmot Cancer Institute; University of Rochester; Rochester NY United States
| | - S. Kambhampati
- Research Medical Center; Sarah Cannon Research Institute; Kansas City MO United States
| | - F. Lansigan
- Department of Hematology; Dartmouth-Hitchcock Medical Center; Lebanon NH United States
| | - J.J. Pu
- Department of Hematology; Penn State Health; Hershey PA United States
| | - A. Skarbnik
- Department of Hematology; John Theurer Cancer Center; Hackensack NJ United States
| | - G. Fonseca
- Florida Cancer Specialists North; Sarah Cannon Research Institute; St. Petersburg FL United States
| | - C. Dorsey
- CLL Program; Leukemia Service, Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - N.M. LaRatta
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - H. Weissbrot
- Columbia University Medical Center; New York-Presbyterian; New York United States
| | - J. Svoboda
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - E.T. Luning Prak
- Clinical Immunology Laboratory; University of Pennsylvania; Philadelphia PA United States
| | - P. Tsao
- Clinical Immunology Laboratory; University of Pennsylvania; Philadelphia PA United States
| | - A. Sitlinger
- Department of Hematology; Duke University Medical Center; Durham NC United States
| | - D. Paskalis
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - P. Sportelli
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - H.P. Miskin
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - M.S. Weiss
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - D.M. Brander
- Department of Hematology; Duke University Medical Center; Durham NC United States
| |
Collapse
|
|
4
|
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol 2018; 28:1050-1056. [PMID: 28453705 DOI: 10.1093/annonc/mdx031] [Citation(s) in RCA: 167] [Impact Index Per Article: 27.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Background Ibrutinib, idelalisib, and venetoclax are approved for treating CLL patients in the United States. However, there is no guidance as to their optimal sequence. Patients and methods We conducted a multicenter, retrospective analysis of CLL patients treated with kinase inhibitors (KIs) or venetoclax. We examined demographics, discontinuation reasons, overall response rates (ORR), survival, and post-KI salvage strategies. Primary endpoint was progression-free survival (PFS). Results A total of 683 patients were identified. Baseline characteristics were similar in the ibrutinib and idelalisib groups. ORR to ibrutinib and idelalisib as first KI was 69% and 81%, respectively. With a median follow-up of 17 months (range 1-60), median PFS and OS for the entire cohort were 35 months and not reached. Patients treated with ibrutinib (versus idelalisib) as first KI had a significantly better PFS in all settings; front-line [hazard ratios (HR) 2.8, CI 1.3-6.3, P = 0.01], relapsed-refractory (HR 2.8, CI 1.9-4.1, P < 0.001), del17p (HR 2.0, CI 1.2-3.4, P = 0.008), and complex karyotype (HR 2.5, CI 1.2-5.2, P = 0.02). At the time of initial KI failure, use of an alternate KI or venetoclax had a superior PFS when compared with chemoimmunotherapy. Furthermore, patients who discontinued ibrutinib due to progression or toxicity had marginally improved outcomes if they received venetoclax (ORR 79%) versus idelalisib (ORR 46%) (PFS HR .6, CI.3-1.0, P = 0.06). Conclusions In the largest real-world experience of novel agents in CLL, ibrutinib appears superior to idelalisib as first KI. Furthermore, in the setting of KI failure, alternate KI or venetoclax therapy appear superior to chemoimmunotherapy combinations. The use of venetoclax upon ibrutinib failure might be superior to idelalisib. These data support the need for trials testing sequencing strategies to optimize treatment algorithms.
Collapse
Affiliation(s)
- A R Mato
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - B T Hill
- Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
| | - N Lamanna
- Division of Hematology and Oncology, New York Presbyterian/Columbia University Medical Center, New York, USA
| | - P M Barr
- Wilmot Cancer Institute, University of Rochester, Rochester, USA
| | - C S Ujjani
- Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, USA
| | | | - C Howlett
- Department of Pharmacy and Clinical Services, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA.,Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, USA
| | - A P Skarbnik
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA
| | - B D Cheson
- Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, USA
| | - C S Zent
- Wilmot Cancer Institute, University of Rochester, Rochester, USA
| | - J J Pu
- Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, USA
| | | | - K Foon
- Celgene Corporation, Summit, USA
| | | | - S Henick Bachow
- Division of Hematology and Oncology, New York Presbyterian/Columbia University Medical Center, New York, USA
| | - A M Winter
- Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
| | - A-L Cruz
- Medstar Washington Hospital Center, Washington, USA
| | - D F Claxton
- Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, USA
| | - A Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA
| | - C Daniel
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - K Isaac
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - K H Kennard
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - C Timlin
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - M Fanning
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - L Gashonia
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - M Yacur
- Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, USA
| | - J Svoboda
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - S J Schuster
- Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - C Nabhan
- Cardinal Health Specialty Solutions, Waukegan, USA
| |
Collapse
|
|
5
|
Ghia P, Coutre S, Furman R, Sharman J, Cheson B, Pagel J, Hillmen P, Barrientos J, Zelenetz A, Kipps T, Flinn I, Eradat H, Lamanna N, Coiffier B, Pettitt A, Li X, Jahn T, O'Brien S, Hallek M. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia. J Geriatr Oncol 2014. [DOI: 10.1016/j.jgo.2014.09.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
|
6
|
Brentjens RJ, Riviere I, Park J, Davilla M, Wang X, Yeh R, Lamanna N, Frattini MG, Sadelain M. Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2534] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
|
7
|
Weiss MA, Heffner L, Lamanna N, Kalaycio M, Schiller G, Coutre S, Maslak P, Jurcic J, Panageas K, Scheinberg DA. A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6516] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. A. Weiss
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Emory Univ, Atlanta, GA; The Cleveland Clinic Fdn, Cleveland, OH; UCLA, Los Angeles, CA; Stanford Univ Medcl Ctr, Stanford, CA
| | - L. Heffner
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Emory Univ, Atlanta, GA; The Cleveland Clinic Fdn, Cleveland, OH; UCLA, Los Angeles, CA; Stanford Univ Medcl Ctr, Stanford, CA
| | - N. Lamanna
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Emory Univ, Atlanta, GA; The Cleveland Clinic Fdn, Cleveland, OH; UCLA, Los Angeles, CA; Stanford Univ Medcl Ctr, Stanford, CA
| | - M. Kalaycio
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Emory Univ, Atlanta, GA; The Cleveland Clinic Fdn, Cleveland, OH; UCLA, Los Angeles, CA; Stanford Univ Medcl Ctr, Stanford, CA
| | - G. Schiller
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Emory Univ, Atlanta, GA; The Cleveland Clinic Fdn, Cleveland, OH; UCLA, Los Angeles, CA; Stanford Univ Medcl Ctr, Stanford, CA
| | - S. Coutre
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Emory Univ, Atlanta, GA; The Cleveland Clinic Fdn, Cleveland, OH; UCLA, Los Angeles, CA; Stanford Univ Medcl Ctr, Stanford, CA
| | - P. Maslak
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Emory Univ, Atlanta, GA; The Cleveland Clinic Fdn, Cleveland, OH; UCLA, Los Angeles, CA; Stanford Univ Medcl Ctr, Stanford, CA
| | - J. Jurcic
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Emory Univ, Atlanta, GA; The Cleveland Clinic Fdn, Cleveland, OH; UCLA, Los Angeles, CA; Stanford Univ Medcl Ctr, Stanford, CA
| | - K. Panageas
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Emory Univ, Atlanta, GA; The Cleveland Clinic Fdn, Cleveland, OH; UCLA, Los Angeles, CA; Stanford Univ Medcl Ctr, Stanford, CA
| | - D. A. Scheinberg
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Emory Univ, Atlanta, GA; The Cleveland Clinic Fdn, Cleveland, OH; UCLA, Los Angeles, CA; Stanford Univ Medcl Ctr, Stanford, CA
| |
Collapse
|
|
8
|
Lamanna N, Weiss MA. Combination therapy with voriconazole and caspofungin for fungal infections in patients with acute leukemia. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- N. Lamanna
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - M. A. Weiss
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
|
9
|
Weiss MA, Lamanna N, Kalaycio M, Jurcic J, Maslak P, Gencarelli A, Scheinberg D, Horgan D. Pentostatin and cyclophosphamide compared to pentostatin, cyclophosphamide, and rituximab as salvage therapy for patients with chronic lymphocytic leukemia. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. A. Weiss
- Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic Foundation, Cleveland, OH
| | - N. Lamanna
- Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic Foundation, Cleveland, OH
| | - M. Kalaycio
- Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic Foundation, Cleveland, OH
| | - J. Jurcic
- Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic Foundation, Cleveland, OH
| | - P. Maslak
- Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic Foundation, Cleveland, OH
| | - A. Gencarelli
- Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic Foundation, Cleveland, OH
| | - D. Scheinberg
- Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic Foundation, Cleveland, OH
| | - D. Horgan
- Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic Foundation, Cleveland, OH
| |
Collapse
|